Literature DB >> 27716747

Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.

D Călugăru1, M Călugăru2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27716747      PMCID: PMC5233938          DOI: 10.1038/eye.2016.214

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  3 in total

Review 1.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

2.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258

3.  Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.

Authors:  F Ricci; M Parravano; F Regine; M Sciamanna; M Tedeschi; F Missiroli; M Varano
Journal:  Eye (Lond)       Date:  2016-05-27       Impact factor: 3.775

  3 in total
  2 in total

1.  Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.

Authors:  F Ricci; M Parravano; F Regine; M Sciamanna; M Tedeschi; F Missiroli; M Varano
Journal:  Eye (Lond)       Date:  2016-10-07       Impact factor: 3.775

2.  High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-08       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.